Biocept posts sixth consecutive growth quarter thanks to increase in commercial test volume
Biocept Inc (NASDAQ: BIOC) posted another record quarter as the commercial provider of liquid biopsy kits for cancer saw an increase in test volume.
The San Diego-based biotech firm delivered revenue of $1.8 million during 4Q 2019, an increase of 108% over the same period last year.
The gain was largely driven by commercial revenue, up 94% compared to 4Q 2018 and 11% over the previous quarter in 2019.
READ: Biocept says published clinical data further validates Target Selector to identify cancer-related mutations
It is the company’s sixth consecutive quarter of growth, CEO Michael Nall told shareholders in a statement Wednesday.
“Our growth for the quarter was driven by year-over-year increases of 46% in commercial test volume and 34% in average reimbursement per patient, predominantly due to reporting on more tests per accession ordered by referring doctors,” Nall said.
Fourth-quarter cost of revenues per accession declined 12% versus the fourth quarter of 2018, the company said.
“While growing revenues, we also benefitted from operating efficiencies, including automation initiatives in our CLIA-certified laboratory,” Nall said. “These efficiencies combined with higher sample volume moved us significantly closer to positive gross margin.”
For its fiscal 2019, Biocept delivered $5.5 million in revenue, a 70% increase from the $3.3 million it posted in 2018.
During the year, the firm launched the first-and-only liquid biopsy test to evaluate cerebrospinal fluid as well as test panels for lung and breast cancer. It also added a new revenue stream via sales of its Target Selector research-use only kits and expanded its intellectual property portfolio with new patents.
In 2019 the firm raised net proceeds of $17.5 million from two equity offerings and warrant exercises.
Its net loss for 4Q 2019 was $5.7 million, or $0.20 per share, down from $6 million, or $1.43 per share during the year-ago period.
Biocept’s shares jumped around 9% in aftermarket trading Wednesday to sit around $0.38.
Contact Angela at [email protected]
Follow her on Twitter @AHarmantas
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/915808/biocept-posts-sixth-consecutive-growth-quarter-thanks-to-increase-in-commercial-test-volume-915808.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).